Frontlight ResearchEarly access
CompletedNo phase
Post Market TRUST - U.S.A. Study
Key facts
- Who runs it
- Acessa Health, Inc.
- Where
- Augusta, Austin, Chicago, Falls Church, Jamaica Plain, Rochester, Santa Monica, Walnut Creek, and West Bloomfield, United StatesSee the 9 sites
- Trial code
- Status
- Completed
- People taking part
- 114 people enrolled
- Started
- 12 Jun 2014
- Ended
- 12 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Global Fibroid Ablation (GFA)
- Abdominal or Laparoscopic Myomectomy
- Uterine Artery Embolization (UAE)
- Record updated
- 30 September 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Are ≥ 18 years old and menstruating
- Have symptomatic uterine fibroids
- Have a uterine size ≤ 16 gestational weeks as determined by pelvic exam
- Have all fibroids that are less than 10 cm in any diameter
- Desire uterine conservation
- Have had a normal Pap smear within the past 36 months defined as "no untreated cervical malignancy or dysplasia."
- Are willing and able to comply with all study tests, procedures, and assessment tools
- Are capable of providing informed consent
Who cannot take part
- Have contraindications for laparoscopic surgery and/or general anesthesia
- Patients requiring major elective concomitant procedures (e.g., hernia repair)
- Have taken any depot gonadotropin releasing hormone (GnRh) agonist within three months prior to the screening procedures
- Have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed at least 10 days prior to treatment
- Have had pelvic radiation
- Have active or history of pelvic inflammatory disease
- Have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the past five years
- Are expected to be high risk for, or are known to have, significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus)
- Are pregnant or lactating
- Have chronic pelvic pain known to not be due to uterine fibroids
- Have known or suspected endometriosis Stage 3 or 4, adenomyosis
- Have a non-uterine pelvic mass over 3 cm
- Have a cervical myoma
- Have one or more completely intracavitary submucous fibroids (Type 0) or only Type 0/1 submucous fibroids that are better treated via hysteroscopic methods
- In the medical judgment of the investigator should not participate in the study
- Are not willing to be randomized to treatment
Where in United States
- Augusta UniversityAugusta, United States
- Texas Fertility CenterAustin, United States
- University of Chicago, Medicine and Biological SciencesChicago, United States
- INOVAFalls Church, United States
- Brigham and Women's HospitalJamaica Plain, United States
- University of Rochester Medical CenterRochester, United States
- University of California, Los AngelesSanta Monica, United States
- Aspen Surgery Center/John Muir HospitalWalnut Creek, United States
- Henry Ford HospitalWest Bloomfield, United States
About the trial
What the trial wants to find out
This Post Market study is being conducted to compare the direct and indirect cost of three approaches (GFA, myomectomy, and uterine artery embolization) for the treatment of symptomatic uterine fibroids. In addition, data from this study is being used to satisfy the requirements of the United States Food and Drug Administration's 522 (post market surveillance) order.
The 2 groups in the trial
- Ablation vs EmbolizationExisting treatment, for comparison
Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
Treatment: Global Fibroid Ablation (GFA) and Uterine Artery Embolization (UAE)
- Ablation vs MyomectomyExisting treatment, for comparison
Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
Treatment: Global Fibroid Ablation (GFA) and Abdominal or Laparoscopic Myomectomy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study
- Record updated
- 30 September 2025